The University of Copenhagen is excited to announce Human Longevity, Inc. as Tier 1 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.

They’ve survived for billions of years in boiling acid, deep-sea vents and salt flats. Now, some of Earth’s oldest life forms — microbes called Archaea — are offering a new weapon in the fight against one of today’s most urgent health threats: antibiotic resistance. In a new study published in Nature Microbiology, researchers at the University of Pennsylvania used artificial intelligence to identify previously unknown compounds in Archaea that could fuel the development of next-generation antibiotics.

Communities supporting America's meat industry have worse air quality and more vulnerable populations compared with similar communities without feedlots, according to new research from the University of Michigan.

Scientists at Tsinghua University have developed a method to grow kidney tumours in the lab using cells from real patients, offering a potential new tool in the fight against renal cancer. Their research, published in the journal Biofabrication, outlines how 3D bioprinting technology can be used to replicate the unique characteristics of each patient’s tumour.

Traditional drug development methods involve identifying a target protin (e.g., a cancer cell receptor) that causes disease, and then searching through countless molecular candidates (potential drugs) that could bind to that protein and block its function. This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug candidates without any prior molecular data—opening up new possibilities for drug discovery.